A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

Completed · Phase 1

Conditions studied: Obesity

In brief

The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.

Key facts

Study ID

NCT05445232

Run by

Eli Lilly and Company

People needed

32

Starts

2022-07-08

Expected to finish

2023-02-24

Last updated by the study team

2023-04-18

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body mass index (BMI) within the range 27.0 to 40.0 kilograms per meter squared (kg/m²)
• Male and female participants of childbearing potential who agree to use contraceptive methods

You may not qualify if…

• Have a history of diabetes or current diagnosis of diabetes
• History or presence of a of significant bleeding disorder
• Participants with significant comorbidity
• Participants receiving treatment with midazolam, warfarin, inhibitors or inducers of cytochrome P450 (CYP) -1A2, CYP2C9, or CYP3A4 enzymes, or drugs are CYP substrates and have a narrow therapeutic index

Where it is running

• Covance Clinical Research Unit — Daytona Beach, Florida, United States
• Covance Dallas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.